Abstract
Cholesteryl ester transfer protein: ace of spades, queen of hearts, or the joker?
Highlights
While industry progressed to clinical studies, academics sought to clarify the relations of cholesteryl ester transfer protein (CETP) activity to reverse cholesterol transport (RCT) and atherosclerosis
An earlier meta-analysis by Dullaart and Sluiter (2008) is of interest. These authors found that B2B2 carriers were less frequent among cases drawn from samples at high cardiovascular disease (CVD) risk than among cases drawn from population-based samples
After following 812 men with coronary heart disease (CHD) on statins for 10 years, the B2 allele was associated with a hazard ratio for CVD death of 1.59 (P = 0.01) despite the expected low CETP activity and high high-density lipoproteins (HDLs) cholesterol
Summary
The hypothesis that CETP inhibition will prevent cardiovascular disease (CVD) was based on the fact that low activity increases HDL cholesterol and decreases LDL cholesterol. After reviewing the literature up to May 2014, Miller (2014) concluded that CETP inhibition is more likely to increase CVD than prevent it, and was of the opinion that ongoing trials should be stopped.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call